

| | |
|---|---|
| C | is $-(CO)_p-(CH_2)_q-(CO)_r-$ or $-(CO)_p-CH=CH-(CO)_r-$, |
| m, p, r | are in each case independently of one another 0 or 1, |
| n, q | are in each case independently of one another 1, 2, 3, or 4, |
| $R^1$ and $R^2$ | are independently of one another H or alkyl, or |
| $R^1$ and $R^2$ | are together |



| | |
|---|---|
| $R^7$, $R^8$, $R^9$, and $R^{10}$ | are each, independently of one another, H, alkyl, Ar, $OR^6$, Hal, $NO_2$, $NR^6R^6$, $NHCOR^6$, CN, $NHSO_2R^6$, $COOR^6$ or $COR^6$, |
| X | is H, Hal, alkyl or Ar, |
| Ar | is phenyl which is unsubstituted or mono-, di- or trisubstituted by $R^3$, $R^4$ or $R^5$ or is unsubstituted naphthyl, |
| $R^3$, $R^4$, $R^5$ | are each, independently of one another, $R^6$, $OR^6$, Hal, $NO_2$, $NR^6R^{6'}$, $NHCOR^6$, CN, $NHSO_2R^6$, $COOR^6$ or $COR^6$, |

$R^6$, $R^{6'}$ are each, independently of one another, H, alkyl, phenyl or benzyl, and

Hal is F, Cl, Br or I,

wherein each optically active amino acid or its derivative is of the D or L configuration;

or a physiologically acceptable salt thereof.

2. (Amended) A compound according to claim 1, wherein said compound is in the form of a single stereoisomer.

4. (Amended) A process for preparing a compound according to Claim 1 comprising

treating with an agent suitable to achieve cyclization a compound of formula III

H-Z-OH III

in which

Z is



,



,




or




and X, A, B and C have the meanings indicated in Claim 1 for a time and under conditions effective to obtain a compound according to claim 1.

5. (Amended) A process for preparing a pharmaceutical composition that contains a compound according to Claim 1 comprising bringing said compound according to Claim 1 into a dose form together with at least one solid, liquid or semi-liquid excipient or auxiliary.

6. (Amended) A pharmaceutical composition comprising at least one compound according to Claim 1, and at least one excipient suitable for sustained administration, parenteral administration, topical application, or administration by inhalation spray.

7. (Amended) A method for the treatment of diseases of the circulation, thromboses, cardiac infarct, coronary heart diseases, arteriosclerosis, apoplexy, angina pectoris, tumours, osteoporosis, inflammations, infections or restenosis after angioplasty, comprising administering to a patient in need thereof an integrin inhibitory effective amount of a compound according to claim 1.

8. (Amended) A method for treating a pathological process that is supported or propagated by angiogenesis, comprising administering to a patient in need thereof of an effective amount of a compound according to claim 1.

20. (Amended) A compound of formula I



I

in which

A is Gly, Ala, derivatized Gly, derivatized Ala or NH-NH-CO,

B is a radical of the formula II



C is $-(CO)_p-(CH_2)_q-(CO)_r-$ or $-(CO)_p-CH=CH-(CO)_r-$,

m, p, r are in each case independently of one another 0 or 1,

n, q are in each case independently of one another 1, 2, 3, or 4,

$R^1$ and $R^2$ are independently of one another H or alkyl, or

$R^1$ and $R^2$ are together




or




$R^7$, $R^8$, $R^9$,

and $R^{10}$ are each, independently of one another, H, alkyl, Ar, $OR^6$, Hal, $NO_2$, $NR^6R^6$, $NHCOR^6$, CN, $NHSO_2R^6$, $COOR^6$ or $COR^6$,

X is H, Hal, alkyl or Ar,

Ar is phenyl which is unsubstituted or mono-, di- or trisubstituted by $R^3$, $R^4$ or $R^5$ or is unsubstituted naphthyl,

$R^3$, $R^4$, $R^5$ are independently of one another $R^6$, $OR^6$, Hal, $NO_2$, $NR^6R^{6'}$, $NHCOR^6$, CN, $NHSO_2R^6$, $COOR^6$ or $COR^6$,

$R^6$, $R^{6'}$ are independently of one another H, alkyl, phenyl or benzyl, and

Hal is F, Cl, Br or I,

wherein each optically active amino acid or its derivative is of the D or L configuration; or a salt thereof.

22. (Amended) A process for the preparation of a compound according to claim 4 comprising

(a) cyclizing a compound of formula III in the presence of an agent suitable to achieve cyclization for a time and under conditions effective to obtain a compound according to claim 1; and

(b) isolating the compound of claim 1.

23. (Amended) A compound according to Claim 1, which is:

a) (8S,14S)-2-(8-(3-guanidinopropyl)-3,6,9,12-tetraxoxo-2,7,10,13-tetraazabicyclo[13.3.1]nonadeca-16,18,19-trien-14-yl)acetic acid or a physiologically acceptable salt thereof;

b) (9S,15S)-2-(9-(3-guanidinopropyl)-3,7,10,13-tetraoxo-2,8,11,14-tetraazabicyclo[14.3.1]eicosan-17,19,20-trien-15-yl)acetic acid or a physiologically acceptable salt thereof;

c) (8S,14S)-(8-(3-guanidinopropyl)-18-methyl-3,6,9,12-tetraoxo-2,7,10,13-tetraazabicyclo[13.3.1]-nonadeca-1(18),15(19),16-trien-14-yl)acetic acid or a physiologically acceptable salt thereof; or

d) (6S,12S)-(6-(3-guanidinopropyl)-4,7,10-trioxo-2,5,8,11-tetraazabicyclo[11.3.1]heptadeca-1(17),13,15-trien-12-yl)acetic acid, or a physiologically acceptable salt thereof.

24. (Amended) A compound according to Claim 1, wherein A is Gly, Ala, derivatized Gly or derivatized Ala, and wherein derivatized Gly is selected from the group consisting of N-methyl, N-ethyl, N-propyl, and N-benzyl, derivatives, and derivatized Ala is selected from the group consisting of N-methyl, N-ethyl, N-propyl, N-benzyl, and $C_{\alpha}$-methyl derivatives.

25. (Amended) A compound according to Claim 20, wherein A is Gly, Ala, derivatized Gly or derivatized Ala, and wherein derivatized Gly is selected from the group consisting of N-methyl, N-ethyl, N-propyl, and N-benzyl, derivatives, and derivatized Ala is selected from the group consisting of N-methyl, N-ethyl, N-propyl, N-benzyl, and $C_{\alpha}$-methyl derivatives.

Please add the following new claims:

--32. A process for preparing a compound according to claim 1 comprising treating with an agent suitable to achieve cyclization a reactive derivative of a compound of formula III for a time and under conditions effective to obtain a compound according to claim 1,

H-Z-OH III

in which

Z is




,




,




or




and X, A, B and C have the meanings indicated in Claim 1.

33. A process for preparing a compound according to claim 1 comprising treating a functional derivative of a compound of the formula I with a solvolysing or hydrogenolysing agent for a time and under conditions effective to obtain a compound according to claim 1.

34. A process for preparing a salt of a compound according to claim 1 comprising treating a compound of formula I with an acid or base to form a salt of the compound according to claim 1.--